A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 6,559 shares of NVS stock, worth $725,163. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,559
Previous 6,327 3.67%
Holding current value
$725,163
Previous $612,000 14.05%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$92.57 - $107.37 $21,476 - $24,909
232 Added 3.67%
6,559 $698,000
Q1 2024

Apr 29, 2024

SELL
$95.27 - $108.47 $7,716 - $8,786
-81 Reduced 1.26%
6,327 $612,000
Q4 2023

Feb 06, 2024

BUY
$92.27 - $101.54 $34,785 - $38,280
377 Added 6.25%
6,408 $647,000
Q3 2023

Nov 13, 2023

SELL
$94.73 - $105.13 $10,041 - $11,143
-106 Reduced 1.73%
6,031 $614,000
Q2 2023

Aug 15, 2023

BUY
$92.52 - $104.91 $5,366 - $6,084
58 Added 0.95%
6,137 $619,000
Q1 2023

Apr 27, 2023

BUY
$80.03 - $92.81 $5,281 - $6,125
66 Added 1.1%
6,079 $559,000
Q4 2022

Feb 07, 2023

SELL
$75.55 - $92.52 $719,160 - $880,697
-9,519 Reduced 61.29%
6,013 $546,000
Q3 2022

Oct 28, 2022

SELL
$74.61 - $87.26 $20,592 - $24,083
-276 Reduced 1.75%
15,532 $1.18 Million
Q2 2022

Aug 12, 2022

BUY
$80.52 - $93.75 $36,636 - $42,656
455 Added 2.96%
15,808 $1.34 Million
Q1 2022

May 04, 2022

BUY
$80.11 - $90.62 $100,057 - $113,184
1,249 Added 8.86%
15,353 $1.35 Million
Q4 2021

Feb 07, 2022

SELL
$79.7 - $88.13 $36,502 - $40,363
-458 Reduced 3.15%
14,104 $1.23 Million
Q3 2021

Nov 02, 2021

BUY
$81.78 - $95.14 $43,261 - $50,329
529 Added 3.77%
14,562 $1.19 Million
Q2 2021

Aug 11, 2021

BUY
$85.24 - $94.15 $1,022 - $1,129
12 Added 0.09%
14,033 $1.28 Million
Q1 2021

May 14, 2021

BUY
$83.5 - $98.47 $40,831 - $48,151
489 Added 3.61%
14,021 $1.2 Million
Q4 2020

Feb 16, 2021

SELL
$78.07 - $94.43 $91,810 - $111,049
-1,176 Reduced 8.0%
13,532 $1.28 Million
Q3 2020

Nov 13, 2020

BUY
$82.14 - $91.0 $6,817 - $7,553
83 Added 0.57%
14,708 $1.28 Million
Q2 2020

Aug 14, 2020

BUY
$80.93 - $91.1 $24,279 - $27,330
300 Added 2.09%
14,625 $1.28 Million
Q1 2020

May 07, 2020

BUY
$70.67 - $99.01 $162,682 - $227,921
2,302 Added 19.15%
14,325 $1.18 Million
Q4 2019

Feb 06, 2020

BUY
$84.35 - $95.37 $386,238 - $436,699
4,579 Added 61.51%
12,023 $1.14 Million
Q3 2019

Nov 05, 2019

BUY
$85.54 - $94.26 $185,108 - $203,978
2,164 Added 40.98%
7,444 $647,000
Q2 2019

Aug 08, 2019

SELL
$75.4 - $92.8 $6,333 - $7,795
-84 Reduced 1.57%
5,280 $482,000
Q1 2019

May 15, 2019

SELL
$75.32 - $86.15 $37,885 - $43,333
-503 Reduced 8.57%
5,364 $516,000
Q4 2018

Jan 31, 2019

BUY
$73.66 - $82.02 $44,785 - $49,868
608 Added 11.56%
5,867 $503,000
Q3 2018

Oct 29, 2018

BUY
$66.94 - $77.43 $27,512 - $31,823
411 Added 8.48%
5,259 $453,000
Q2 2018

Jul 19, 2018

SELL
$64.91 - $73.36 $683,177 - $772,114
-10,525 Reduced 68.46%
4,848 $366,000
Q1 2018

Apr 17, 2018

SELL
$70.39 - $84.15 $518,140 - $619,428
-7,361 Reduced 32.38%
15,373 $1.24 Million
Q4 2017

Jan 17, 2018

BUY
$72.33 - $77.64 $62,782 - $67,391
868 Added 3.97%
22,734 $1.91 Million
Q3 2017

Oct 24, 2017

BUY
$74.14 - $77.27 $1.62 Million - $1.69 Million
21,866
21,866 $1.88 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $238B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Benjamin F. Edwards & Company, Inc. Portfolio

Follow Benjamin F. Edwards & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.